Third Rock Ventures

Third Rock Ventures expands, strengthens team

Wednesday, May 15, 2013 09:38 AM

Third Rock Ventures, a venture capital firm focused on building healthcare companies, has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies and the overall strategy and direction of the firm.

More... »

Quest Diagnostics

Third Rock Ventures raises $516M Fund III

Monday, March 25, 2013 11:56 AM

Third Rock Ventures, a venture capital firm, announced the final closing of Fund III, raising $516 million in an oversubscribed fund. With Fund III, Third Rock will continue to execute on its strategy of launching, building and supporting transformative healthcare companies.

More... »


Third Rock Ventures names entrepreneur-in-residence

Tuesday, October 2, 2012 01:57 PM

Boston-based Third Rock Ventures, a venture capital firm focused on building life sciences companies, has named Felix W. Frueh, Ph.D., an entrepreneur-in-residence (EIR). As an EIR, Dr. Frueh will provide strategic input on new and existing portfolio companies with a particular focus on personalized medicine.

More... »

Third Rock launches MyoKardia with $38M for genetic heart disease

Friday, September 21, 2012 10:51 AM

Third Rock Ventures, a venture capital firm of Boston, Mass., has formed new company MyoKardia with a $38 million Series A financing. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

More... »

Allena Pharmaceuticals secures $15 million in Series A financing

Wednesday, November 16, 2011 03:03 PM

Allena Pharmaceuticals, a company developing and commercializing innovative non-systemic oral protein therapeutics, has secured $15 million in Series A venture capital financing. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the round. Proceeds from the financing will be used to accelerate the development of Allena's non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.

More... »

Zafgen receives $33 million in Series C financing

Friday, July 8, 2011 01:00 PM

Zafgen, a pharmaceutical company, announced the closing of a $33 million Series C financing led by the existing investor syndicate, including Atlas Venture and Third Rock Ventures. The financing will be used to support development of Zafgen's pipeline and to advance its lead methionine aminopeptidase 2 (MetAP2) inhibitor for the treatment of severe obesity into phase II clinical studies.

More... »


CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs